FidoCure®

Biotechnology ResearchCalifornia, United States11-50 Employees

FidoCure® is an AI-driven personalized therapeutics engine for canine cancer, developed by One Health Company. Leveraging the genetic similarities between canine and human cancers, FidoCure combines genomic, clinical, and real-world evidence to help veterinarians make more informed, individualized treatment decisions.

Through its proprietary next-generation DNA sequencing test, FidoCure has built the world’s largest canine cancer genomics dataset, enabling more effective and accessible targeted therapies. FidoCure’s work has been published in Nature Precision Oncology and Nature Scientific Reports.

Backed by leading biotech investors including Polaris Ventures, Andreessen Horowitz (a16z), and Y Combinator, FidoCure is advancing personalized cancer care for dogs while generating insights relevant to human health.

Sign up for free to view info

Email Format Employee directory